WALTHAM, Mass., Jan. 18 /PRNewswire/ -- Decision Biomarkers Inc., a leading developer of protein biomarker analysis systems for pharmaceutical research and development, announced the launch of the AVANTRA(TM) biomarker workstation along with its innovative MAX BIOCHIP(TM) 8-plex cytokine immunoassay. The system's ease-of-use enables users to generate data in real-time, accelerating decision making and improving project productivity.
The AVANTRA(TM) biomarker workstation is the first multiplexed immunoassay system that enables non-specialized technicians to perform complex protein biomarker analyses in both the lab and directly at clinical trial sites. Plasma and serum samples can be analyzed on site by virtually anyone in real time. The system eliminates the need to send samples out to a specialized lab.
One emerging application for DBI's technology is adaptive clinical trials where data is needed quickly for fast decision making. "Plasma and serum samples can now be analyzed on-site immediately after collection, lowering costs and streamlining the clinical-trials process" commented Roger Dowd, President and CEO of Decision Biomarkers. 'With the growing trend in adaptive clinical trials, rapidly acquiring data with the AVANTRA(TM) -- an hour after collection, versus several weeks or months from a core lab -- greatly accelerates decision making and the progress of clinical trials."
Researchers in biomarker validation, preclinical and translational medicine programs are interested as well. According to Peter Maimonis, VP Biological Research at Decision Biomarkers, "By fully automating the multiplexed protein assay, we specifically designed the AVANTRA(TM) system with individual investigators and researchers in mind. The scientists that we target want to spend their time on higher value activities rather than focusing on the minutia of running immunoassays."
The new MAX BIOCHIP(TM) immunoassay cartridges providing fully automated and multiplexed immunoassays complement the AVANTRA(TM) workstation. The 8-plex cytokine biochip introduced with the AVANTRA(TM) is positioned to support research in inflammation, autoimmune response, oncology, infectious disease and vaccines. Other immunoassay biochips are planned for introduction later this year including a 10-plex angiogenesis panel and multiplex cardiovascular panel. DBI is also developing biomarker panels with customized content defined by the Company's collaborators.
About Decision Biomarkers Inc.
Decision Biomarkers is a privately-held life science tools company that has developed the next-generation technology for protein biomarker analysis. DBI is driving the widespread adoption of protein biomarker analysis with the first automated, multiplex immunoassay system that can be used in real-time by virtually anyone, anywhere in drug development, clinical trials and diagnostics.
Copyright (C) 2008 Decision Biomarkers Inc. All rights reserved.
|SOURCE Decision Biomarkers Inc.|
Copyright©2008 PR Newswire.
All rights reserved